Click for best price
IBSC Drugs Market Size, Share 2022
Market Analysis and Insights: Global IBSC Drugs Market
The global IBSC Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global IBSC Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global IBSC Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global IBSC Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global IBSC Drugs market.
Global IBSC Drugs Scope and Market Size
IBS-C Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global IBS-C Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the IBS-C Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Segment by Application
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- Taiwan
- Indonesia
- Thailand
- Malaysia
- Philippines
- Vietnam
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- U.A.E
By Company
- Catalent Pharmaceuticals Solutions
- Nestle
- Abbott Laboratories
- Synergy Pharmaceuticals
- Sucampo Pharmaceuticals
- Novartis Pharma Ag
- Astellas Pharmaceuticals
- Ardelyx, Inc
- Synthetic Biologics, Inc
- Teva Pharmaceutical Industries
- Bama-Geve, SLU
- Ferring BV
- Ironwood Pharmaceuticals, Inc
- Salix Pharmaceuticals Ltd
- Norgine B.V
- Prometheus Laboratories Inc
- Actavis Nordic A/S
- Albireo Pharma Inc
- Yuhan Corp
- Astrazeneca Plc
- The Menarini Group
- Ono Pharmaceutical Co., Ltd
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes IBSC Drugs product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of IBSC Drugs, with price, sales, revenue, and global market share of IBSC Drugs from 2019 to 2022.
Chapter 3, the IBSC Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the IBSC Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the IBSC Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of IBSC Drugs.
Chapter 13, 14, and 15, to describe IBSC Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 IBSC Drugs Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global and United States IBS-C Drugs Market Report & Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
128 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Study Coverage
1.1 IBS-C Drugs Product Introduction
1.2 Global IBS-C Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global IBS-C Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global IBS-C Drugs Sales in Volume for the Year 2017-2028
1.3 United States IBS-C Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States IBS-C Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States IBS-C Drugs Sales in Volume for the Year 2017-2028
1.4 IBS-C Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States IBS-C Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of IBS-C Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 IBS-C Drugs Market Dynamics
1.5.1 IBS-C Drugs Industry Trends
1.5.2 IBS-C Drugs Market Drivers
1.5.3 IBS-C Drugs Market Challenges
1.5.4 IBS-C Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 IBS-C Drugs Market Segment by Type
2.1.1 Linaclotide
2.1.2 Lubiprostone
2.1.3 Osmotic Laxatives
2.1.4 Stimulant Laxatives
2.1.5 Others
2.2 Global IBS-C Drugs Market Size by Type
2.2.1 Global IBS-C Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global IBS-C Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global IBS-C Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States IBS-C Drugs Market Size by Type
2.3.1 United States IBS-C Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States IBS-C Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States IBS-C Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 IBS-C Drugs Market Segment by Application
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Online Pharmacies
3.2 Global IBS-C Drugs Market Size by Application
3.2.1 Global IBS-C Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global IBS-C Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global IBS-C Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States IBS-C Drugs Market Size by Application
3.3.1 United States IBS-C Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States IBS-C Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States IBS-C Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global IBS-C Drugs Competitor Landscape by Company
4.1 Global IBS-C Drugs Market Size by Company
4.1.1 Top Global IBS-C Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global IBS-C Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global IBS-C Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global IBS-C Drugs Price by Manufacturer (2017-2022)
4.2 Global IBS-C Drugs Concentration Ratio (CR)
4.2.1 IBS-C Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of IBS-C Drugs in 2021
4.2.3 Global IBS-C Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global IBS-C Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global IBS-C Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers IBS-C Drugs Product Type
4.3.3 Date of International Manufacturers Enter into IBS-C Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States IBS-C Drugs Market Size by Company
4.5.1 Top IBS-C Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States IBS-C Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States IBS-C Drugs Sales by Players (2020, 2021 & 2022)
5 Global IBS-C Drugs Market Size by Region
5.1 Global IBS-C Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global IBS-C Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global IBS-C Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global IBS-C Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global IBS-C Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global IBS-C Drugs Sales in Value by Region: 2017-2022
5.3.2 Global IBS-C Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America IBS-C Drugs Market Size YoY Growth 2017-2028
6.1.2 North America IBS-C Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific IBS-C Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific IBS-C Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe IBS-C Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe IBS-C Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America IBS-C Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America IBS-C Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa IBS-C Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa IBS-C Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Catalent Pharmaceuticals Solutions
7.1.1 Catalent Pharmaceuticals Solutions Corporation Information
7.1.2 Catalent Pharmaceuticals Solutions Description and Business Overview
7.1.3 Catalent Pharmaceuticals Solutions IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Catalent Pharmaceuticals Solutions IBS-C Drugs Products Offered
7.1.5 Catalent Pharmaceuticals Solutions Recent Development
7.2 Nestle
7.2.1 Nestle Corporation Information
7.2.2 Nestle Description and Business Overview
7.2.3 Nestle IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Nestle IBS-C Drugs Products Offered
7.2.5 Nestle Recent Development
7.3 Abbott Laboratories
7.3.1 Abbott Laboratories Corporation Information
7.3.2 Abbott Laboratories Description and Business Overview
7.3.3 Abbott Laboratories IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Abbott Laboratories IBS-C Drugs Products Offered
7.3.5 Abbott Laboratories Recent Development
7.4 Synergy Pharmaceuticals
7.4.1 Synergy Pharmaceuticals Corporation Information
7.4.2 Synergy Pharmaceuticals Description and Business Overview
7.4.3 Synergy Pharmaceuticals IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Synergy Pharmaceuticals IBS-C Drugs Products Offered
7.4.5 Synergy Pharmaceuticals Recent Development
7.5 Sucampo Pharmaceuticals
7.5.1 Sucampo Pharmaceuticals Corporation Information
7.5.2 Sucampo Pharmaceuticals Description and Business Overview
7.5.3 Sucampo Pharmaceuticals IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Sucampo Pharmaceuticals IBS-C Drugs Products Offered
7.5.5 Sucampo Pharmaceuticals Recent Development
7.6 Novartis Pharma Ag
7.6.1 Novartis Pharma Ag Corporation Information
7.6.2 Novartis Pharma Ag Description and Business Overview
7.6.3 Novartis Pharma Ag IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Novartis Pharma Ag IBS-C Drugs Products Offered
7.6.5 Novartis Pharma Ag Recent Development
7.7 Astellas Pharmaceuticals
7.7.1 Astellas Pharmaceuticals Corporation Information
7.7.2 Astellas Pharmaceuticals Description and Business Overview
7.7.3 Astellas Pharmaceuticals IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Astellas Pharmaceuticals IBS-C Drugs Products Offered
7.7.5 Astellas Pharmaceuticals Recent Development
7.8 Ardelyx, Inc
7.8.1 Ardelyx, Inc Corporation Information
7.8.2 Ardelyx, Inc Description and Business Overview
7.8.3 Ardelyx, Inc IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Ardelyx, Inc IBS-C Drugs Products Offered
7.8.5 Ardelyx, Inc Recent Development
7.9 Synthetic Biologics, Inc
7.9.1 Synthetic Biologics, Inc Corporation Information
7.9.2 Synthetic Biologics, Inc Description and Business Overview
7.9.3 Synthetic Biologics, Inc IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Synthetic Biologics, Inc IBS-C Drugs Products Offered
7.9.5 Synthetic Biologics, Inc Recent Development
7.10 Teva Pharmaceutical Industries
7.10.1 Teva Pharmaceutical Industries Corporation Information
7.10.2 Teva Pharmaceutical Industries Description and Business Overview
7.10.3 Teva Pharmaceutical Industries IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Teva Pharmaceutical Industries IBS-C Drugs Products Offered
7.10.5 Teva Pharmaceutical Industries Recent Development
7.11 Bama-Geve, SLU
7.11.1 Bama-Geve, SLU Corporation Information
7.11.2 Bama-Geve, SLU Description and Business Overview
7.11.3 Bama-Geve, SLU IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Bama-Geve, SLU IBS-C Drugs Products Offered
7.11.5 Bama-Geve, SLU Recent Development
7.12 Ferring BV
7.12.1 Ferring BV Corporation Information
7.12.2 Ferring BV Description and Business Overview
7.12.3 Ferring BV IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Ferring BV Products Offered
7.12.5 Ferring BV Recent Development
7.13 Ironwood Pharmaceuticals, Inc
7.13.1 Ironwood Pharmaceuticals, Inc Corporation Information
7.13.2 Ironwood Pharmaceuticals, Inc Description and Business Overview
7.13.3 Ironwood Pharmaceuticals, Inc IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Ironwood Pharmaceuticals, Inc Products Offered
7.13.5 Ironwood Pharmaceuticals, Inc Recent Development
7.14 Salix Pharmaceuticals Ltd
7.14.1 Salix Pharmaceuticals Ltd Corporation Information
7.14.2 Salix Pharmaceuticals Ltd Description and Business Overview
7.14.3 Salix Pharmaceuticals Ltd IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Salix Pharmaceuticals Ltd Products Offered
7.14.5 Salix Pharmaceuticals Ltd Recent Development
7.15 Norgine B.V
7.15.1 Norgine B.V Corporation Information
7.15.2 Norgine B.V Description and Business Overview
7.15.3 Norgine B.V IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Norgine B.V Products Offered
7.15.5 Norgine B.V Recent Development
7.16 Prometheus Laboratories Inc
7.16.1 Prometheus Laboratories Inc Corporation Information
7.16.2 Prometheus Laboratories Inc Description and Business Overview
7.16.3 Prometheus Laboratories Inc IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.16.4 Prometheus Laboratories Inc Products Offered
7.16.5 Prometheus Laboratories Inc Recent Development
7.17 Actavis Nordic A/S
7.17.1 Actavis Nordic A/S Corporation Information
7.17.2 Actavis Nordic A/S Description and Business Overview
7.17.3 Actavis Nordic A/S IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.17.4 Actavis Nordic A/S Products Offered
7.17.5 Actavis Nordic A/S Recent Development
7.18 Albireo Pharma Inc
7.18.1 Albireo Pharma Inc Corporation Information
7.18.2 Albireo Pharma Inc Description and Business Overview
7.18.3 Albireo Pharma Inc IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.18.4 Albireo Pharma Inc Products Offered
7.18.5 Albireo Pharma Inc Recent Development
7.19 Yuhan Corp
7.19.1 Yuhan Corp Corporation Information
7.19.2 Yuhan Corp Description and Business Overview
7.19.3 Yuhan Corp IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.19.4 Yuhan Corp Products Offered
7.19.5 Yuhan Corp Recent Development
7.20 Astrazeneca Plc
7.20.1 Astrazeneca Plc Corporation Information
7.20.2 Astrazeneca Plc Description and Business Overview
7.20.3 Astrazeneca Plc IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.20.4 Astrazeneca Plc Products Offered
7.20.5 Astrazeneca Plc Recent Development
7.21 The Menarini Group
7.21.1 The Menarini Group Corporation Information
7.21.2 The Menarini Group Description and Business Overview
7.21.3 The Menarini Group IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.21.4 The Menarini Group Products Offered
7.21.5 The Menarini Group Recent Development
7.22 Ono Pharmaceutical Co., Ltd
7.22.1 Ono Pharmaceutical Co., Ltd Corporation Information
7.22.2 Ono Pharmaceutical Co., Ltd Description and Business Overview
7.22.3 Ono Pharmaceutical Co., Ltd IBS-C Drugs Sales, Revenue and Gross Margin (2017-2022)
7.22.4 Ono Pharmaceutical Co., Ltd Products Offered
7.22.5 Ono Pharmaceutical Co., Ltd Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 IBS-C Drugs Industry Chain Analysis
8.2 IBS-C Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 IBS-C Drugs Distributors
8.3 IBS-C Drugs Production Mode & Process
8.4 IBS-C Drugs Sales and Marketing
8.4.1 IBS-C Drugs Sales Channels
8.4.2 IBS-C Drugs Distributors
8.5 IBS-C Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. IBS-C Drugs CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. IBS-C Drugs Market Trends
Table 3. IBS-C Drugs Market Drivers
Table 4. IBS-C Drugs Market Challenges
Table 5. IBS-C Drugs Market Restraints
Table 6. Global IBS-C Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States IBS-C Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global IBS-C Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States IBS-C Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top IBS-C Drugs Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global IBS-C Drugs Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global IBS-C Drugs Revenue Share by Manufacturer, 2017-2022
Table 13. Global IBS-C Drugs Sales by Manufacturer, (K Pcs), 2017-2022
Table 14. Global IBS-C Drugs Sales Share by Manufacturer, 2017-2022
Table 15. Global IBS-C Drugs Price by Manufacturer (2017-2022) & (USD/Pcs)
Table 16. Global IBS-C Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global IBS-C Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in IBS-C Drugs as of 2021)
Table 18. Top Players of IBS-C Drugs in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers IBS-C Drugs Product Type
Table 20. Date of International Manufacturers Enter into IBS-C Drugs Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top IBS-C Drugs Players in United States Market, Ranking by Revenue (2021)
Table 23. United States IBS-C Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States IBS-C Drugs Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States IBS-C Drugs Sales by Players, (K Pcs), 2020, 2021 & 2022
Table 26. United States IBS-C Drugs Sales Share by Players, 2020, 2021 & 2022
Table 27. Global IBS-C Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global IBS-C Drugs Sales in Volume by Region (2017-2022) & (K Pcs)
Table 29. Global IBS-C Drugs Sales in Volume Forecast by Region (2023-2028) & (K Pcs)
Table 30. Global IBS-C Drugs Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global IBS-C Drugs Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America IBS-C Drugs Sales in Volume by Country (2017-2028) & (K Pcs)
Table 33. North America IBS-C Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific IBS-C Drugs Sales in Volume by Region (2017-2028) & (K Pcs)
Table 35. Asia Pacific IBS-C Drugs Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe IBS-C Drugs Sales in Volume by Country (2017-2028) & (K Pcs)
Table 37. Europe IBS-C Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America IBS-C Drugs Sales in Volume by Country (2017-2028) & (K Pcs)
Table 39. Latin Americaa IBS-C Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa IBS-C Drugs Sales in Volume by Country (2017-2028) & (K Pcs)
Table 41. Middle East and Africa IBS-C Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Catalent Pharmaceuticals Solutions Corporation Information
Table 43. Catalent Pharmaceuticals Solutions Description and Business Overview
Table 44. Catalent Pharmaceuticals Solutions IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 45. Catalent Pharmaceuticals Solutions IBS-C Drugs Product
Table 46. Catalent Pharmaceuticals Solutions Recent Development
Table 47. Nestle Corporation Information
Table 48. Nestle Description and Business Overview
Table 49. Nestle IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 50. Nestle Product
Table 51. Nestle Recent Development
Table 52. Abbott Laboratories Corporation Information
Table 53. Abbott Laboratories Description and Business Overview
Table 54. Abbott Laboratories IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 55. Abbott Laboratories Product
Table 56. Abbott Laboratories Recent Development
Table 57. Synergy Pharmaceuticals Corporation Information
Table 58. Synergy Pharmaceuticals Description and Business Overview
Table 59. Synergy Pharmaceuticals IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 60. Synergy Pharmaceuticals Product
Table 61. Synergy Pharmaceuticals Recent Development
Table 62. Sucampo Pharmaceuticals Corporation Information
Table 63. Sucampo Pharmaceuticals Description and Business Overview
Table 64. Sucampo Pharmaceuticals IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 65. Sucampo Pharmaceuticals Product
Table 66. Sucampo Pharmaceuticals Recent Development
Table 67. Novartis Pharma Ag Corporation Information
Table 68. Novartis Pharma Ag Description and Business Overview
Table 69. Novartis Pharma Ag IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 70. Novartis Pharma Ag Product
Table 71. Novartis Pharma Ag Recent Development
Table 72. Astellas Pharmaceuticals Corporation Information
Table 73. Astellas Pharmaceuticals Description and Business Overview
Table 74. Astellas Pharmaceuticals IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 75. Astellas Pharmaceuticals Product
Table 76. Astellas Pharmaceuticals Recent Development
Table 77. Ardelyx, Inc Corporation Information
Table 78. Ardelyx, Inc Description and Business Overview
Table 79. Ardelyx, Inc IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 80. Ardelyx, Inc Product
Table 81. Ardelyx, Inc Recent Development
Table 82. Synthetic Biologics, Inc Corporation Information
Table 83. Synthetic Biologics, Inc Description and Business Overview
Table 84. Synthetic Biologics, Inc IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 85. Synthetic Biologics, Inc Product
Table 86. Synthetic Biologics, Inc Recent Development
Table 87. Teva Pharmaceutical Industries Corporation Information
Table 88. Teva Pharmaceutical Industries Description and Business Overview
Table 89. Teva Pharmaceutical Industries IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 90. Teva Pharmaceutical Industries Product
Table 91. Teva Pharmaceutical Industries Recent Development
Table 92. Bama-Geve, SLU Corporation Information
Table 93. Bama-Geve, SLU Description and Business Overview
Table 94. Bama-Geve, SLU IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 95. Bama-Geve, SLU Product
Table 96. Bama-Geve, SLU Recent Development
Table 97. Ferring BV Corporation Information
Table 98. Ferring BV Description and Business Overview
Table 99. Ferring BV IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 100. Ferring BV Product
Table 101. Ferring BV Recent Development
Table 102. Ironwood Pharmaceuticals, Inc Corporation Information
Table 103. Ironwood Pharmaceuticals, Inc Description and Business Overview
Table 104. Ironwood Pharmaceuticals, Inc IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 105. Ironwood Pharmaceuticals, Inc Product
Table 106. Ironwood Pharmaceuticals, Inc Recent Development
Table 107. Salix Pharmaceuticals Ltd Corporation Information
Table 108. Salix Pharmaceuticals Ltd Description and Business Overview
Table 109. Salix Pharmaceuticals Ltd IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 110. Salix Pharmaceuticals Ltd Product
Table 111. Salix Pharmaceuticals Ltd Recent Development
Table 112. Norgine B.V Corporation Information
Table 113. Norgine B.V Description and Business Overview
Table 114. Norgine B.V IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 115. Norgine B.V Product
Table 116. Norgine B.V Recent Development
Table 117. Prometheus Laboratories Inc Corporation Information
Table 118. Prometheus Laboratories Inc Description and Business Overview
Table 119. Prometheus Laboratories Inc IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 120. Prometheus Laboratories Inc Product
Table 121. Prometheus Laboratories Inc Recent Development
Table 122. Actavis Nordic A/S Corporation Information
Table 123. Actavis Nordic A/S Description and Business Overview
Table 124. Actavis Nordic A/S IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 125. Actavis Nordic A/S Product
Table 126. Actavis Nordic A/S Recent Development
Table 127. Albireo Pharma Inc Corporation Information
Table 128. Albireo Pharma Inc Description and Business Overview
Table 129. Albireo Pharma Inc IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 130. Albireo Pharma Inc Product
Table 131. Albireo Pharma Inc Recent Development
Table 132. Yuhan Corp Corporation Information
Table 133. Yuhan Corp Description and Business Overview
Table 134. Yuhan Corp IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 135. Yuhan Corp Product
Table 136. Yuhan Corp Recent Development
Table 137. Astrazeneca Plc Corporation Information
Table 138. Astrazeneca Plc Description and Business Overview
Table 139. Astrazeneca Plc IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 140. Astrazeneca Plc Product
Table 141. Astrazeneca Plc Recent Development
Table 142. The Menarini Group Corporation Information
Table 143. The Menarini Group Description and Business Overview
Table 144. The Menarini Group IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 145. The Menarini Group Product
Table 146. The Menarini Group Recent Development
Table 147. Ono Pharmaceutical Co., Ltd Corporation Information
Table 148. Ono Pharmaceutical Co., Ltd Description and Business Overview
Table 149. Ono Pharmaceutical Co., Ltd IBS-C Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 150. Ono Pharmaceutical Co., Ltd Product
Table 151. Ono Pharmaceutical Co., Ltd Recent Development
Table 152. Key Raw Materials Lists
Table 153. Raw Materials Key Suppliers Lists
Table 154. IBS-C Drugs Customers List
Table 155. IBS-C Drugs Distributors List
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources
List of Figures
Figure 1. IBS-C Drugs Product Picture
Figure 2. Global IBS-C Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global IBS-C Drugs Market Size 2017-2028 (US$ Million)
Figure 4. Global IBS-C Drugs Sales 2017-2028 (K Pcs)
Figure 5. United States IBS-C Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States IBS-C Drugs Market Size 2017-2028 (US$ Million)
Figure 7. United States IBS-C Drugs Sales 2017-2028 (K Pcs)
Figure 8. United States IBS-C Drugs Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States IBS-C Drugs Market Share in Global, in Volume (K Pcs) 2017-2028
Figure 10. IBS-C Drugs Report Years Considered
Figure 11. Product Picture of Linaclotide
Figure 12. Product Picture of Lubiprostone
Figure 13. Product Picture of Osmotic Laxatives
Figure 14. Product Picture of Stimulant Laxatives
Figure 15. Product Picture of Others
Figure 16. Global IBS-C Drugs Market Share by Type in 2022 & 2028
Figure 17. Global IBS-C Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 18. Global IBS-C Drugs Sales Market Share in Value by Type (2017-2028)
Figure 19. Global IBS-C Drugs Sales by Type (2017-2028) & (K Pcs)
Figure 20. Global IBS-C Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 21. Global IBS-C Drugs Price by Type (2017-2028) & (USD/Pcs)
Figure 22. United States IBS-C Drugs Market Share by Type in 2022 & 2028
Figure 23. United States IBS-C Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 24. United States IBS-C Drugs Sales Market Share in Value by Type (2017-2028)
Figure 25. United States IBS-C Drugs Sales by Type (2017-2028) & (K Pcs)
Figure 26. United States IBS-C Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 27. United States IBS-C Drugs Price by Type (2017-2028) & (USD/Pcs)
Figure 28. Product Picture of Hospital Pharmacies
Figure 29. Product Picture of Retail Pharmacies
Figure 30. Product Picture of Online Pharmacies
Figure 31. Global IBS-C Drugs Market Share by Application in 2022 & 2028
Figure 32. Global IBS-C Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 33. Global IBS-C Drugs Sales Market Share in Value by Application (2017-2028)
Figure 34. Global IBS-C Drugs Sales by Application (2017-2028) & (K Pcs)
Figure 35. Global IBS-C Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 36. Global IBS-C Drugs Price by Application (2017-2028) & (USD/Pcs)
Figure 37. United States IBS-C Drugs Market Share by Application in 2022 & 2028
Figure 38. United States IBS-C Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 39. United States IBS-C Drugs Sales Market Share in Value by Application (2017-2028)
Figure 40. United States IBS-C Drugs Sales by Application (2017-2028) & (K Pcs)
Figure 41. United States IBS-C Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 42. United States IBS-C Drugs Price by Application (2017-2028) & (USD/Pcs)
Figure 43. North America IBS-C Drugs Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 44. North America IBS-C Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 45. U.S. IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 46. Canada IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 47. Europe IBS-C Drugs Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 48. Europe IBS-C Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 49. Germany IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. France IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. U.K. IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 52. Italy IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 53. Russia IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 54. Asia-Pacific IBS-C Drugs Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 55. Asia-Pacific IBS-C Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 56. China IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. Japan IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. South Korea IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. India IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. Australia IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Taiwan IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Indonesia IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. Thailand IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 64. Malaysia IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 65. Philippines IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 66. Latin America IBS-C Drugs Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 67. Latin America IBS-C Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 68. Mexico IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 69. Brazil IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 70. Argentina IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 71. Middle East & Africa IBS-C Drugs Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 72. Middle East & Africa IBS-C Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 73. Turkey IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 74. Saudi Arabia IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 75. U.A.E IBS-C Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 76. IBS-C Drugs Value Chain
Figure 77. IBS-C Drugs Production Process
Figure 78. Channels of Distribution
Figure 79. Distributors Profiles
Figure 80. Bottom-up and Top-down Approaches for This Report
Figure 81. Data Triangulation
Figure 82. Key Executives Interviewed
